Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863057 · ClinicalTrials.gov registry record · Phase 2
Combination Pain Therapy in HIV Neuropathy
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00863057 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 15 participants.
The verdict
NCT00863057, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Neuropathy results from damage to the nerves in the feet and legs. It is usually experienced as pain, tingling or numbness. In HIV-infected people, neuropathy can result from the infection itself or be a side effect of antiretroviral treatment. The purpose of this study is to determine whether two different drugs, methadone and duloxetine, reduce neuropathy-associated pain in HIV-infected people. This study will also examine whether utilization of both of these drugs is more effective than treatment with only one.
Interventions
- DRUG Duloxetine
- DRUG Methadone
- DRUG Duloxetine placebo
- DRUG Methadone placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863057
The ClinicalTrials.gov registry entry for NCT00863057 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Duloxetine is the first listed.
NCT00863057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863057 about?
NCT00863057 is a clinical study titled "Combination Pain Therapy in HIV Neuropathy". Neuropathy results from damage to the nerves in the feet and legs. It is usually experienced as pain, tingling or numbness. In HIV-infected people, neuropathy can result from the infection itself or be a side effect of antiretroviral treatment. The purpose of this study is to determine whether two d...
What is the current status of trial NCT00863057?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00863057?
The interventions under investigation include: Duloxetine (DRUG), Methadone (DRUG), Duloxetine placebo (DRUG), Methadone placebo (DRUG).
Who is sponsoring clinical trial NCT00863057?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.